相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Importance of Evaluation of DNA Amplificability in KRAS Mutation Testing with Dideoxy Sequencing using Formalin-fixed and Paraffin-embedded Colorectal Cancer Tissues
Naoko Okayama et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
Chen Mao et al.
MOLECULAR BIOLOGY REPORTS (2011)
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer
Pedro Pinto et al.
CANCER GENETICS (2011)
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman et al.
CANCER RESEARCH (2010)
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
Jolien Tol et al.
EUROPEAN JOURNAL OF CANCER (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
Irene Lurkin et al.
PLOS ONE (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors
Martin Pichler et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
EGFR Antagonists in Cancer Treatment
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer
Lisa Simi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Li Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations
Chuan-Hsiang Huang et al.
SCIENCE (2007)
Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf
Greg Buhrman et al.
STRUCTURE (2007)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit
Nabil Miled et al.
SCIENCE (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Rare cancer-specific mutations in PIK3CA show gain of function
Marco Gymnopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
J. R. Jass
HISTOPATHOLOGY (2007)
Oncogenic PI3K deregulates transcription and translation
AG Bader et al.
NATURE REVIEWS CANCER (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The prevalence of PIK3CA mutations in gastric and colon cancer
S Velho et al.
EUROPEAN JOURNAL OF CANCER (2005)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
Functional analysis of PIK3CA gene mutations in human colorectal cancer
T Ikenoue et al.
CANCER RESEARCH (2005)
Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis
C Willmore-Payne et al.
HUMAN PATHOLOGY (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Cancer genes and the pathways they control
B Vogelstein et al.
NATURE MEDICINE (2004)
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
C Oliveira et al.
ONCOGENE (2003)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
